Loomis, Sayles & Company
LGND icon

Loomis, Sayles & Company’s Ligand Pharmaceuticals LGND Stock Holding History

Loomis, Sayles & Company’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.2M Sell
291,805
-61,404
-17% -$14.5M 0.12% 66
2026
Q1 		$70.5M Sell
353,209
-29,468
-8% -$5.83M 0.09% 72
2025
Q4 		$72.4M Sell
382,677
-17,876
-4% -$3.43M 0.09% 71
2025
Q3 		$71M Sell
400,553
-10,344
-3% -$1.54M 0.08% 77
2025
Q2 		$46.7M Sell
410,897
-9,937
-2% -$1.06M 0.06% 109
2025
Q1 		$44.2M Buy
420,834
+23,134
+6% +$2.62M 0.06% 119
2024
Q4 		$42.6M Buy
397,700
+24,921
+7% +$2.82M 0.05% 140
2024
Q3 		$37.3M Buy
372,779
+114,436
+44% +$11.5M 0.05% 163
2024
Q2 		$21.8M Buy
+258,343
New +$20.6M 0.03% 248
2018
Q3 		– Sell
-83
Closed -$11K – 925
2018
Q2 		$11K Sell
83
-15
-15% -$1.67K ﹤0.01% 790
2018
Q1 		$10K Sell
98
-348
-78% -$34.4K ﹤0.01% 807
2017
Q4 		$38K Buy
446
+113
+34% +$9.79K ﹤0.01% 641
2017
Q3 		$28K Buy
333
+227
+214% +$18K ﹤0.01% 703
2017
Q2 		$8K Buy
+106
New +$7.42K ﹤0.01% 817
2017
Q1 		– Sell
-175
Closed -$11K – 1004
2016
Q4 		$11K Hold
175
– – ﹤0.01% 831
2016
Q3 		$11K Hold
175
– – ﹤0.01% 752
2016
Q2 		$13K Sell
175
-179
-51% -$13.3K ﹤0.01% 701
2016
Q1 		$24K Buy
354
+312
+743% +$19K ﹤0.01% 708
2015
Q4 		$3K Buy
+42
New +$2.59K ﹤0.01% 964

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company's LGND Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Ligand Pharmaceuticals (LGND) stake by 17% in Q2 2026, selling an estimated $14.5M and leaving 291,805 shares worth $92.2M. The position accounts for 0.12% of the portfolio, ranked #66.

Loomis, Sayles & Company first reported a position in LGND in Q4 2015 and has held it in 19 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Loomis, Sayles & Company held 291,805 shares of Ligand Pharmaceuticals worth $92.2M as of Q2 2026.
  • Loomis, Sayles & Company sold 61,404 Ligand Pharmaceuticals shares in Q2 2026, an estimated $14.5M.
  • Ligand Pharmaceuticals made up 0.12% of Loomis, Sayles & Company's portfolio in Q2 2026, its #66 holding.
  • Loomis, Sayles & Company first reported a position in Ligand Pharmaceuticals in Q4 2015 and has held it in 19 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.